Table 2.
Associations between genetically predicted SMOX activity from SSI-IHPS newborn cohort (SSI-IHPS instrument) and SMOX expression from the EGCUT adult cohort (EGCUT instrument), based on SNP rs1741315, and six site-specific cancers (prostate, breast, lung, colorectal and neuroblastoma).
| Outcome | Cases, No | Controls, No | EAF | SSI-IHPS instrument | EGCUT instrument | ||
|---|---|---|---|---|---|---|---|
| Odds ratio (95% CI) | P | Odds ratio (95% CI) | P | ||||
| Prostate cancer | 79,194 | 61,112 | 0.430 | 0.98 (0.96–1.00) | 0.046 | 0.96 (0.92–1.00) | 0.046 |
| Breast cancer | 62,533 | 60,976 | 0.434 | 0.99 (0.96–1.02) | 0.465 | 0.98 (0.93–1.03) | 0.465 |
| Lung cancer | 29,266 | 56,450 | 0.442 | 0.97 (0.94–1.00) | 0.084 | 0.95 (0.89–1.01) | 0.084 |
| Colorectal cancer | 5,693 | 386,740 | 0.439 | 0.96 (0.91–1.01) | 0.097 | 0.92 (0.83–1.02) | 0.097 |
| Gastric cancer | 6,563 | 195,745 | 0.361 | 1.02 (0.97–1.07) | 0.543 | 1.03 (0.93–1.14) | 0.543 |
| Neuroblastoma | 2,101 | 4,202 | 0.412 | 1.07 (0.97–1.19) | 0.182 | 1.16 (0.93–1.44) | 0.182 |
All estimations were based on the Wald ratio method, with A being the effect allele. EAF, effect allele frequency in each cohort (cases and controls combined); P, p-value. An increased spermidine/spermine ratio represents increased SMOX activity.